-
1.Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors 有权
标题翻译: 2,4-二氨基嘧啶作为ALK和c-Met抑制剂的稠合双环衍生物公开(公告)号:US08148391B2
公开(公告)日:2012-04-03
申请号:US12162851
申请日:2007-10-23
申请人: Gulzar Ahmed , Henry Joseph Breslin , Jason Burke , Matthew A. Curry , James L. Diebold , Bruce Dorsey , Benjamin J. Dugan , Daming Feng , Diane E. Gingrich , Tao Guo , Keith S. Learn , Joseph G. Lisko , Rong-Qiang Liu , Eugen Florin Mesaros , Karen Milkiewicz , Gregory R. Ott , Jay P. Theroff , Tho V. Thieu , Rabindranath Tripathy , Theodore L. Underiner , Gregory J. Wells , Craig A. Zificsak
发明人: Gulzar Ahmed , Henry Joseph Breslin , Jason Burke , Matthew A. Curry , James L. Diebold , Bruce Dorsey , Benjamin J. Dugan , Daming Feng , Diane E. Gingrich , Tao Guo , Keith S. Learn , Joseph G. Lisko , Rong-Qiang Liu , Eugen Florin Mesaros , Karen Milkiewicz , Gregory R. Ott , Jay P. Theroff , Tho V. Thieu , Rabindranath Tripathy , Theodore L. Underiner , Gregory J. Wells , Craig A. Zificsak
IPC分类号: A61K31/505 , C07D239/02
CPC分类号: C07D239/48 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14
摘要: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
摘要翻译: 本发明提供式I或II化合物或其药学上可接受的盐形式,其中R1,R2,R3,R4,R5,A1,A2,A3,A4和A5如本文所定义。 式I或II的化合物具有ALK和/或c-Met抑制活性,并且可用于治疗增殖性疾病。
-
2.Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors 有权
标题翻译: 2,4-二氨基嘧啶的双酚衍生物作为ALK和c-MET抑制剂公开(公告)号:US20120165519A1
公开(公告)日:2012-06-28
申请号:US13413322
申请日:2012-03-06
申请人: Gulzar Ahmed , Henry Joseph Breslin , Jason Burke , Matthew A. Curry , James L. Diebold , Bruce Dorsey , Benjamin J. Dugan , Daming Feng , Diane E. Gingrich , Tao Guo , Keith S. Learn , Joseph G. Lisko , Rong-qiang Liu , Eugen Mesaros , Karen Milkiewicz , Gregory R. Ott , Jay P. Theroff , Tho V. Thieu , Rabindranath Tripathy , Theodore L. Underiner , Gregory J. Wells , Craig A. Zificsak
发明人: Gulzar Ahmed , Henry Joseph Breslin , Jason Burke , Matthew A. Curry , James L. Diebold , Bruce Dorsey , Benjamin J. Dugan , Daming Feng , Diane E. Gingrich , Tao Guo , Keith S. Learn , Joseph G. Lisko , Rong-qiang Liu , Eugen Mesaros , Karen Milkiewicz , Gregory R. Ott , Jay P. Theroff , Tho V. Thieu , Rabindranath Tripathy , Theodore L. Underiner , Gregory J. Wells , Craig A. Zificsak
IPC分类号: C07D403/14 , C07D498/04 , C07D413/12 , C07D409/14 , C07D405/12 , C07D417/14 , C07D401/14 , C07D405/14 , C07D403/12 , C07D413/14
CPC分类号: C07D239/48 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14
摘要: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
摘要翻译: 本发明提供式I或II化合物或其药学上可接受的盐形式,其中R1,R2,R3,R4,R5,A1,A2,A3,A4和A5如本文所定义。 式I或II的化合物具有ALK和/或c-Met抑制活性,并且可用于治疗增殖性疾病。
-
3.FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS 有权
标题翻译: 2,4-二氨基嘧啶作为ALK和c-MET抑制剂的熔融双相衍生物公开(公告)号:US20090221555A1
公开(公告)日:2009-09-03
申请号:US12162851
申请日:2007-10-23
申请人: Gulzar Ahmed , Adolph Bohnstedt , Henry Joseph Breslin , Jason Burke , Matthew A. Curry , James L. Diebold , Bruce Dorsey , Benjamin J. Dugan , Daming Feng , Diane E. Gingrich , Tao Guo , Koc-Kan Ho , Keith S. Learn , Joseph G. Lisko , Rong-qiang Liu , Eugen Mesaros , Karen Milkiewicz , Gregory R. Ott , Jonathan Parrish , Jay P. Theroff , Tho V. Thieu , Rabindranath Tripathy , Theodore L. Underiner , Jason C. Wagner , Linda Weinberg , Gregory J. Wells , Ming You , Craig A. Zificsak
发明人: Gulzar Ahmed , Adolph Bohnstedt , Henry Joseph Breslin , Jason Burke , Matthew A. Curry , James L. Diebold , Bruce Dorsey , Benjamin J. Dugan , Daming Feng , Diane E. Gingrich , Tao Guo , Koc-Kan Ho , Keith S. Learn , Joseph G. Lisko , Rong-qiang Liu , Eugen Mesaros , Karen Milkiewicz , Gregory R. Ott , Jonathan Parrish , Jay P. Theroff , Tho V. Thieu , Rabindranath Tripathy , Theodore L. Underiner , Jason C. Wagner , Linda Weinberg , Gregory J. Wells , Ming You , Craig A. Zificsak
IPC分类号: A61K31/55 , C07D239/02 , A61K31/505 , C07D403/00 , C07D413/14 , A61K31/5377 , C07D413/00 , C07D403/14
CPC分类号: C07D239/48 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14
摘要: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
摘要翻译: 本发明提供式I或II化合物或其药学上可接受的盐形式,其中R1,R2,R3,R4,R5,A1,A2,A3,A4和A5如本文所定义。 式I或II的化合物具有ALK和/或c-Met抑制活性,并且可用于治疗增殖性疾病。
-
4.Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors 有权
标题翻译: 2,4-二氨基嘧啶作为ALK和c-MET抑制剂的稠合双环衍生物公开(公告)号:US08552186B2
公开(公告)日:2013-10-08
申请号:US13413322
申请日:2012-03-06
申请人: Gulzar Ahmed , Henry J. Breslin , Jason Burke , Matthew A. Curry , James L. Diebold , Bruce D. Dorsey , Benjamin J. Dugan , Daming Feng , Diane E. Gingrich , Tao Guo , Keith S. Learn , Joseph Lisko , Rong-qiang Liu , Eugen F. Mesaros , Karen L. Milkiewicz , Gregory R. Ott , Jay P. Theroff , Tho Thieu , Rabindranath Tripathy , Theodore L. Underiner , Gregory J. Wells , Craig A. Zificsak
发明人: Gulzar Ahmed , Henry J. Breslin , Jason Burke , Matthew A. Curry , James L. Diebold , Bruce D. Dorsey , Benjamin J. Dugan , Daming Feng , Diane E. Gingrich , Tao Guo , Keith S. Learn , Joseph Lisko , Rong-qiang Liu , Eugen F. Mesaros , Karen L. Milkiewicz , Gregory R. Ott , Jay P. Theroff , Tho Thieu , Rabindranath Tripathy , Theodore L. Underiner , Gregory J. Wells , Craig A. Zificsak
IPC分类号: C07D403/12
CPC分类号: C07D239/48 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14
摘要: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
摘要翻译: 本发明提供式I或II化合物或其药学上可接受的盐形式,其中R1,R2,R3,R4,R5,A1,A2,A3,A4和A5如本文所定义。 式I或II的化合物具有ALK和/或c-Met抑制活性,并且可用于治疗增殖性疾病。
-
公开(公告)号:US08471005B2
公开(公告)日:2013-06-25
申请号:US13160890
申请日:2011-06-15
申请人: Henry J. Breslin , Sankar Chatterjee , James L. Diebold , Bruce D. Dorsey , Derek D. Dunn , Diane E. Gingrich , Greg A. Hostetler , Robert L. Hudkins , Rachael Hunter , Kurt A. Josef , Joseph Lisko , Eugen F. Mesaros , Karen L. Milkiewicz , Gregory R. Ott , Babu G. Sundar , Jay P. Theroff , Tho Thieu , Rabindranath Tripathy , Theodore L. Underiner , Linda Weinberg , Gregory J. Wells , Craig A. Zificsak
发明人: Henry J. Breslin , Sankar Chatterjee , James L. Diebold , Bruce D. Dorsey , Derek D. Dunn , Diane E. Gingrich , Greg A. Hostetler , Robert L. Hudkins , Rachael Hunter , Kurt A. Josef , Joseph Lisko , Eugen F. Mesaros , Karen L. Milkiewicz , Gregory R. Ott , Babu G. Sundar , Jay P. Theroff , Tho Thieu , Rabindranath Tripathy , Theodore L. Underiner , Linda Weinberg , Gregory J. Wells , Craig A. Zificsak
IPC分类号: C07D487/04 , C07D403/12 , A61K31/53 , A61K31/5377 , A61P35/00
CPC分类号: C07D487/04
摘要: The present invention provides a compound of formula I or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula I has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.
摘要翻译: 本发明提供式I化合物或其盐形式,其中Q 1,Q 2,Q 3和Q 4如本文所定义。 式I化合物具有ALK和/或JAK2抑制活性,可用于治疗增殖性疾病。
-
公开(公告)号:US20120028919A1
公开(公告)日:2012-02-02
申请号:US13160890
申请日:2011-06-15
申请人: Henry J. Breslin , Sankar Chatterjee , James L. Diebold , Bruce D. Dorsey , Derek D. Dunn , Diane E. Gingrich , Greg A. Hostetler , Robert L. Hudkins , Rachael Hunter , Kurt A. Josef , Joseph Lisko , Eugen F. Mesaros , Karen L. Milkiewicz , Gregory R. Ott , Babu G. Sundar , Jay P. Theroff , Tho Thieu , Rabindranath Tripathy , Theodore L. Underiner , Linda Weinberg , Gregory J. Wells , Craig A. Zificsak
发明人: Henry J. Breslin , Sankar Chatterjee , James L. Diebold , Bruce D. Dorsey , Derek D. Dunn , Diane E. Gingrich , Greg A. Hostetler , Robert L. Hudkins , Rachael Hunter , Kurt A. Josef , Joseph Lisko , Eugen F. Mesaros , Karen L. Milkiewicz , Gregory R. Ott , Babu G. Sundar , Jay P. Theroff , Tho Thieu , Rabindranath Tripathy , Theodore L. Underiner , Linda Weinberg , Gregory J. Wells , Craig A. Zificsak
IPC分类号: A61K31/5377 , C07D223/16 , A61P35/00 , A61K31/53 , A61K31/695 , C07D487/04 , A61K31/55
CPC分类号: C07D487/04
摘要: The present invention provides a compound of formula I or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula I has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.
摘要翻译: 本发明提供式I化合物或其盐形式,其中Q 1,Q 2,Q 3和Q 4如本文所定义。 式I化合物具有ALK和/或JAK2抑制活性,可用于治疗增殖性疾病。
-
7.Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE) 有权
标题翻译: 作为基质金属蛋白酶和TNF-α转化酶(TACE)的抑制剂的螺环β-氨基酸衍生物公开(公告)号:US06962938B2
公开(公告)日:2005-11-08
申请号:US10741326
申请日:2003-12-18
申请人: Gregory R. Ott , Xiao Tao Chen , Jingwu Duan , Matthew E. Voss
发明人: Gregory R. Ott , Xiao Tao Chen , Jingwu Duan , Matthew E. Voss
IPC分类号: A61P1/04 , A61P19/02 , A61P35/04 , C07D307/94 , C07D317/72 , C07D319/08 , C07D339/06 , C07D405/12 , C07D407/12 , C07D409/12 , C07D417/12 , C07D417/14 , C07D491/04 , A61K31/403 , A61K31/38 , C07D207/04 , C07D207/18 , C07D327/04
CPC分类号: C07D317/72 , C07D307/94 , C07D319/08 , C07D339/06 , C07D405/12 , C07D407/12 , C07D409/12 , C07D417/12 , C07D417/14 , C07D491/04
摘要: The present application describes novel spiro-cyclic β-amino acid derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 3-13 membered carbocycle or heterocycle, ring C forms a 3-11 membered spiro-carbocycle or spiro-heterocycleon ring B, and the other variables are defined in the present specification, which are useful as as matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), and/or aggrecanase inhibitors.
摘要翻译: 本申请描述了式I的新型螺环β-氨基酸衍生物或其药学上可接受的盐形式,其中环B是3-13元碳环或杂环,环C形成3-11元螺 - 碳环或螺 - 杂环B,其他变量在本说明书中定义,其可用作基质金属蛋白酶(MMP),TNF-α转化酶(TACE)和/或软骨聚集蛋白聚糖酶抑制剂。
-
8.Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF- &agr; converting enzyme (TACE) 有权
标题翻译: 作为基质金属蛋白酶和/或TNF-α转化酶(TACE)的抑制剂的环状异羟肟酸公开(公告)号:US06740649B2
公开(公告)日:2004-05-25
申请号:US10244626
申请日:2002-09-16
申请人: Gregory R. Ott , Xiao-Tao Chen , Jingwu Duan , Zhonghui Lu
发明人: Gregory R. Ott , Xiao-Tao Chen , Jingwu Duan , Zhonghui Lu
IPC分类号: A61K3154
CPC分类号: C07D235/06 , C07D209/08 , C07D215/12 , C07D235/08 , C07D235/10 , C07D235/24 , C07D279/16 , C07D401/12 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/12 , C07D413/10 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D475/08 , C07D491/04
摘要: The present application describes novel cyclic hydroxamic acids of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NR1, and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), aggrecanase or a combination thereof, pharmaceutical compositions containing the same, and methods of using the same.
摘要翻译: 本申请描述了式I的新型环状异羟肟酸或其药学上可接受的盐形式,其中环B为5-7元环系,其含有0-2个选自O,N,NR 1和S( O)p和0-1个羰基,其它变量在本说明书中定义,其可用作基质金属蛋白酶(MMP),TNF-α转化酶(TACE),聚蛋白聚糖蛋白聚糖酶或其组合的抑制剂,药物组合物 含有相同的含义,以及使用它们的方法。
-
9.Spiro-cyclic &bgr;-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-&agr; converting enzyme (TACE) 有权
标题翻译: 作为基质金属蛋白酶和TNF-α转化酶(TACE)的抑制剂的螺环β-氨基酸衍生物公开(公告)号:US06720329B2
公开(公告)日:2004-04-13
申请号:US10096804
申请日:2002-03-12
申请人: Gregory R. Ott , Xiao Tao Chen , Jingwu Duan , Matthew E. Voss
发明人: Gregory R. Ott , Xiao Tao Chen , Jingwu Duan , Matthew E. Voss
IPC分类号: A61K31443
CPC分类号: C07D317/72 , C07D307/94 , C07D319/08 , C07D339/06 , C07D405/12 , C07D407/12 , C07D409/12 , C07D417/12 , C07D417/14 , C07D491/04
摘要: The present application describes novel spiro-cyclic &bgr;-amino acid derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 3-13 membered carbocycle or heterocycle, ring C forms a 3-11 membered spiro-carbocycle or spiro-heterocycleon ring B, and the other variables are defined in the present specification, which are useful as as matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), and/or aggrecanase inhibitors.
摘要翻译: 本申请描述了式I的新型螺环β-氨基酸衍生物或其药学上可接受的盐形式,其中环B是3-13元碳环或杂环,环C形成3-11元螺 - 碳环或螺 - 杂环B,其他变量在本说明书中定义,其可用作基质金属蛋白酶(MMP),TNF-α转化酶(TACE)和/或软骨聚集蛋白聚糖酶抑制剂。
-
-
-
-
-
-
-
-